KINAXO Enters into US and Japanese Partnerships to Introduce its Cellular Target Profiling™ Service

KINAXO Biotechnologies GmbH announced that it has entered into strategic sales and marketing partnerships with BioCatalyst International and BioFocus DPI to support the introduction of KINAXO’s Cellular Target Profiling™ Service within the US and Japanese market.

The KINAXO Cellular Target Profiling Service enables drug developers to determine the native cellular protein interactions of small molecule compounds in a physiological setting. This provides significant benefits to any drug development program, since knowledge of the compound’s proteome-wide on/off-target activities supports the prediction of its performance in clinical trials.

KINAXO chose to partner with BioCatalyst and BioFocus DPI due to their hands-on experience in supporting high value drug discovery services. Both partners will work closely with the KINAXO management and scientific team to ensure qualified, personalized support in the US and Japan.

BioCatalyst International, a New York based company, specializes in the introduction and development of early market drug discovery products and services. BioCatalyst maintains a team of experienced PhD scientist and business development associates to properly communicate and support all the high value aspects of KINAXO’s Cellular Target Profiling Service. This will allow KINAXO to serve its US customers with direct, local support.

In Japan, KINAXO has partnered with BioFocus DPI, a global drug discovery service provider with headquarters in the United Kingdom. BioFocus DPI offers a range of target-to-drug discovery products and services to support pharmaceutical companies in their drug development process. BioFocus DPI will help KINAXO establish a wide presence in Japan through its broad network of pharmaceutical relationships and intimate knowledge of the Japanese market.